Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

High Frequency of Clinically Significant Mutations after First-Line Generic Highly Active Antiretroviral Therapy Failure: Implications for Second-Line Options in Resource-Limited Settings

N. Kumarasamy, Vidya Madhavan, Kartik K. Venkatesh, S. Saravanan, Rami Kantor, P. Balakrishnan, Bella Devaleenal, S. Poongulali, Tokugha Yepthomi, Suniti Solomon, Kenneth H. Mayer, Constance Benson and Robert Schooley
Clinical Infectious Diseases
Vol. 49, No. 2 (Jul. 15, 2009), pp. 306-309
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/40308672
Page Count: 4
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
High Frequency of Clinically Significant Mutations after First-Line Generic Highly Active Antiretroviral Therapy Failure: Implications for Second-Line Options in Resource-Limited Settings
Preview not available

Abstract

Continuation of failed highly active antiretroviral therapy regimens can lead to the accumulation of mutations that may limit options for second-line treatment. We studied the pattern of drug resistance mutations among 138 Indian patients who experienced failure of nonnudeotide reverse-transcriptase-containing first-line highly active antiretroviral therapy. This study demonstrates a high frequency of drug resistance mutations in human immunodeficiency virus-infected Indians who experience immunologic treatment failure and suggests the need for viral load monitoring.

Page Thumbnails

  • Thumbnail: Page 
306
    306
  • Thumbnail: Page 
307
    307
  • Thumbnail: Page 
[308]
    [308]
  • Thumbnail: Page 
309
    309